Osteomyelitis Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Osteomyelitis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Osteomyelitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively.

Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Osteomyelitis - Overview
3. Osteomyelitis - Therapeutics Development
4. Pipeline Overview
5. Pipeline by Companies
6. Products under Development by Companies
7. Osteomyelitis - Therapeutics Assessment
8. Assessment by Target
9. Assessment by Mechanism of Action
10. Assessment by Route of Administration
11. Assessment by Molecule Type
12. Osteomyelitis - Companies Involved in Therapeutics Development

• Allergan Plc
• CrystalGenomics Inc
• Debiopharm International SA
• Motif Bio Plc
• Nabriva Therapeutics AG
• Vyome Biosciences Pvt Ltd

For more information about this report visit https://www.researchandmarkets.com/research/bkh83j/osteomyelitis